Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV

Background Despite the availability of highly effective direct-acting antivirals (DAAs) and the expected treatment as prevention (TasP) effect, transmission of hepatitis C virus (HCV) persists in men who have sex with men (MSM) who engage in high-risk sexual behaviours. Aim We aimed to estimate the incidence of primary HCV infection among MSM living with HIV in France when DAA was readily available. Methods We used data from a large French hospital cohort of persons living with HIV (ANRS CO4-FHDH) prospectively collected between 2014 and 2017. HCV incidence rates were calculated using person-time methods for HCV-negative MSM at inclusion who had serological follow-up from 1 January 2014 to 31 December 2017. Sensitivity analyses were performed by varying the main assumptions to assess their impact on the results. Results Of 14,273 MSM living with HIV who were initially HCV-seronegative, 330 acquired HCV during follow-up over 45,866 person-years (py), resulting in an overall estimated incidence rate of 0.72/100 py (95% CI: 0.65–0.80). HCV incidence significantly decreased from 0.98/100 py (95% CI: 0.81–1.19) in 2014 to 0.45/100 py (95% CI: 0.35–0.59) in 2017 (54% decrease; 95% CI: 36–67). This trend was confirmed by most of the sensitivity analyses. Conclusion The primary incidence of HCV was halved for MSM living with HIV between 2014 and 2017. This decrease may be related to unrestricted DAA availability in France for individuals living with HIV. Further interventions, including risk reduction, are needed to reach HCV micro-elimination in MSM living with HIV.

Download Full-text

Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV

HIV Medicine ◽

10.1111/hiv.12502 ◽

2017 ◽

Vol 18 (9) ◽

pp. 685-689 ◽

Cited By ~ 7

Author(s):

A Mena ◽

H Meijide ◽

I Rodríguez-Osorio ◽

A Castro ◽

E Poveda

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Persons Living With Hiv ◽

Chronic Hepatitis C Virus ◽

Living With Hiv ◽

Related Mortality

Download Full-text

Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV

AIDS ◽

10.1097/qad.0000000000002461 ◽

2020 ◽

Vol 34 (4) ◽

pp. 599-608 ◽

Cited By ~ 1

Author(s):

Caroline Besson ◽

Nicolas Noel ◽

Remi Lancar ◽

Sophie Prevot ◽

Michele Algarte-Genin ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Hepatitis B Virus ◽

Hepatitis B ◽

People Living With Hiv ◽

B Virus ◽

Living With Hiv ◽

Lymphoma Risk

Download Full-text

Sociocultural Factors Influencing The Transmission of HIV/AIDS in The United States

10.1093/med/9780199392742.003.0009 ◽

2017 ◽

Author(s):

Robert E Fullilove

Keyword(s):

United States ◽

Criminal Justice ◽

Correctional Facility ◽

The United States ◽

Hiv Care ◽

Sociocultural Factors ◽

Effective Interventions ◽

Persons Living With Hiv ◽

Living With Hiv ◽

Hiv Aids

This chapter discusses the unique impact that social disadvantage in general and the criminal justice systems in the United States in particular have on the conditions that drive the HIV/AIDS epidemic in this country. HIV/AIDS is classified as an important racial/ethnic health disparity because residents of marginalized black and Hispanic communities are overrepresented among persons living with HIV/AIDS in the United States. Members of black and Hispanic communities are also overrepresented in the criminal justice; in terms of the epidemic, approximately one out of seven persons living with HIV/AIDS will pass through a U.S. correctional facility in any given year. A history of incarceration is associated with poor treatment outcomes for HIV illness. Improving the quality of HIV care in correctional facilities and in the communities to which incarcerated persons will return is imperative, as is effective interventions in incarcerated populations and communities. Having AIDS activists, scientists, and healthcare workers join in efforts to reform incarceration policies and practices will improve efforts to prevent and treat HIV/AIDS, particularly in communities that confront high rates of HIV/AIDS and incarceration.

Download Full-text

Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV

AIDS ◽

10.1097/qad.0000000000002562 ◽

2020 ◽

Vol 34 (9) ◽

pp. 1347-1358

Author(s):

Samira Hosseini-Hooshyar ◽

Marianne Martinello ◽

Jasmine Yee ◽

Phillip Read ◽

David Baker ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Therapy ◽

Universal Access ◽

People Living With Hiv ◽

Reinfection Rate ◽

Direct Acting Antiviral ◽

Direct Acting ◽

Living With Hiv

Download Full-text

The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV

AIDS ◽

10.1097/qad.0000000000002610 ◽

2020 ◽

Vol 34 (11) ◽

pp. 1681-1683

Author(s):

Edward R. Cachay ◽

Francesca J. Torriani ◽

Lucas Hill ◽

Sonia Jain ◽

Azucena Del Real ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Barriers To Care ◽

People Living With Hiv ◽

Living With Hiv

Download Full-text

Association between chronic hepatitis C virus infection and myocardial infarction in people living with HIV in the United States

10.1101/453860 ◽

2018 ◽

Author(s):

Jessica Williams-Nguyen ◽

Stephen E Hawes ◽

Robin M Nance ◽

Sara Lindström ◽

Susan R Heckbert ◽

...

Keyword(s):

Myocardial Infarction ◽

Hepatitis C Virus ◽

Hepatitis C ◽

The United States ◽

Hcv Rna ◽

High Risk Population ◽

People Living With Hiv ◽

Extrahepatic Manifestations ◽

Chronic Hcv ◽

Living With Hiv

AbstractHepatitis C virus (HCV) is common among people living with HIV (PLWH). The potential for extrahepatic manifestations of HCV, including myocardial infarction (MI), is a topic of active research. MI is classified into types, predominantly atheroembolic Type 1 MI (T1MI) and supply-demand mismatch Type 2 MI (T2MI). We examined the association between HCV and MI in the CFAR Network of Integrated Clinical Systems (CNICS), a multi-center clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Universal MI definition. We estimated the association between chronic HCV (RNA+) and time to MI adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics and substance use. Among 24,755 PLWH aged ≥18, there were 336 T1MI and 330 T2MI during a median of 4.2 years of follow-up. HCV was associated with a 68% greater risk of T2MI (adjusted hazard ratio (aHR) 1.68, 95% CI: 1.22, 2.30) but not T1MI (aHR 0.96, 95% CI: 0.63, 1.45). In a cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR 2.26, 95% CI: 1.34, 3.81). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.

Download Full-text

Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV

BMJ Case Reports ◽

10.1136/bcr-2019-230529 ◽

2019 ◽

Vol 12 (10) ◽

pp. e230529 ◽

Cited By ~ 2

Author(s):

Charisse Mandimika ◽

Onyema Ogbuagu

Keyword(s):

Hepatitis C Virus ◽

Pregnant Woman ◽

Hepatitis C ◽

Perinatal Transmission ◽

Hcv Infection ◽

Hiv Protease ◽

Virologic Suppression ◽

Simplex Virus ◽

Direct Acting ◽

Living With Hiv

A 30-year-old woman living with HIV was diagnosed with genotype 2b hepatitis C virus (HCV) infection during the second trimester of her pregnancy. She had achieved virologic suppression on an HIV protease inhibitor-based regimen and had recurrent genital herpes simplex virus infection managed with antivirals. Given the risk of perinatal transmission of HCV and to avoid performing a caesarean section, after multidisciplinary consultations and consideration of the limited data on safety on HCV direct-acting antivirals (DAAs) in pregnancy, she consented to and was successfully treated with a 6-week lead-in course of sofosbuvir (SOF) alone followed by a 6-week course of SOF and velpatasvir postpartum. This resulted in cure of her HCV infection. The neonate tested negative for HCV at birth and was healthy without birth defects 2 years postdelivery. Our case highlights a successful HCV treatment approach in a pregnant woman with newer DAAs.

Download Full-text